Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025)
Telix Pharmaceuticals (TLX) posted quarterly Non-Current Debt of $391.9 million for Q4 2025, up 8.6% year-over-year from $360.9 million in Q4 2024, and up 8.6% quarter-over-quarter from $360.9 million in Q4 2024.
Telix Pharmaceuticals (TLX) Non-Current Debt (2023 - 2025) Analysis & Trends
Telix Pharmaceuticals (TLX) has reported Non-Current Debt for 3 consecutive years, with $391.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Non-Current Debt rose 8.6% year-over-year to $391.9 million; the TTM figure through Dec 2025 stood at $391.9 million (up 8.6% YoY), while the FY2025 annual figure was $391.9 million, up 14.66% from the prior year.
- Non-Current Debt grew to $391.9 million in Q4 2025 per TLX's latest filing, from $360.9 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $391.9 million in Q4 2025 and bottomed at $5.3 million in Q4 2023.
- Historically, Non-Current Debt has averaged $252.7 million across 3 years, with a median of $360.9 million in 2024.
- Annual changes were most pronounced in 2024 — Non-Current Debt jumped 6652.77% — and 2025, when it rose 8.6%.
- Telix Pharmaceuticals' Non-Current Debt stood at $5.3 million in 2023, then soared by 6652.77% to $360.9 million in 2024, then gained by 8.6% to $391.9 million in 2025.
- Business Quant data shows TLX's Non-Current Debt at $391.9 million in Q4 2025, $360.9 million in Q4 2024, and $5.3 million in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 882.16 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 8.96 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 546.77 Mn |
| 10 | Telix Pharmaceuticals | 4.00 Bn | 3.86 Bn | - | 391.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 391.91 Mn |
| Dec 31, 2024 | 360.87 Mn |
| Dec 31, 2023 | 5.34 Mn |